Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder (CAMP)

This study has been completed.
Information provided by (Responsible Party):
National Institute of Mental Health (NIMH) Identifier:
First received: January 16, 2007
Last updated: December 7, 2015
Last verified: November 2010
Results First Received: November 16, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Single Blind (Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Schizophrenia
Schizoaffective Disorder
Interventions: Drug: Risperidone
Drug: Olanzapine
Drug: Quetiapine
Drug: Aripiprazole

  Participant Flow

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Switch Group Participants will switch to aripiprazole.
Stay Group Participants will continue treatment with olanzapine, quetiapine, or risperidone.
Total Total of all reporting groups

Baseline Measures
    Switch Group     Stay Group     Total  
Number of Participants  
[units: participants]
  109     106     215  
[units: participants]
<=18 years     0     0     0  
Between 18 and 65 years     109     106     215  
>=65 years     0     0     0  
[units: years]
Mean (Standard Deviation)
  40  (11.7)     42  (10.5)     41  (11.1)  
[units: participants]
Female     41     37     78  
Male     68     69     137  
Region of Enrollment  
[units: participants]
United States     109     106     215  
non-HDL cholesterol  
[units: mg/dL]
Mean (Standard Deviation)
  169  (31.9)     176  (33.5)     173  (32.8)  

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Mean Difference in Non-HDL Cholesterol Level Changes Between Patients Assigned to Stay Compared to Patients Assigned to Switch at the Last Observation   [ Time Frame: Measured at Month 6 ]

2.  Secondary:   Efficacy Failure, Defined as Psychiatric Hospitalization, a 25 Percent Increase From Baseline on the Positive and Negative Syndrome Scale or Substantial Clinical Deterioration on the Clinical Global Impressions-Change (CGI-C)   [ Time Frame: Measured at Month 6 ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Open-label treatment is a limitation of this study, particularly for outcomes not measured in the laboratory but instead subject to clinical judgment.

  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Dr. Scott Stroup
Organization: Columbia University
phone: 212-543-5676


Responsible Party: National Institute of Mental Health (NIMH) Identifier: NCT00423878     History of Changes
Other Study ID Numbers: STROUP06STN0
DSIR AT-AP ( Other Identifier: National Institute of Mental Health )
Study First Received: January 16, 2007
Results First Received: November 16, 2012
Last Updated: December 7, 2015
Health Authority: United States: Federal Government